After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting--A single-institution experience.

G. Scandurra,Eleonora Taibi,Rosa Anna Aiello,Maurizio Chiarenza,A. Mazzola,M. Vita Sano,Eleonora Miano,G. Fallica,Michele Caruso

After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting--A single-institution experience.

2010

G. Scandurra
Eleonora Taibi
Rosa Anna Aiello
Maurizio Chiarenza
A. Mazzola
M. Vita Sano
Eleonora Miano
G. Fallica
Michele Caruso

1136 Background: Trastuzumab received in 2006 the European Medicines Agency approval for the adjuvant treatment of patients affected by HER2-overexpressing early breast cancer after the results of ...

Keywords:

HERA
Physical therapy
Breast cancer
Adjuvant
Trastuzumab
Chemotherapy
Medicine
Internal medicine
Oncology
previously treated
first line therapy
single institution
hera trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations